Production (Stage)
Cidara Therapeutics, Inc.
CDTX
$24.28
-$1.42-5.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 55.11% | -227.23% | -- | -- | -221.38% |
| Total Depreciation and Amortization | -16.95% | -3.28% | -- | -- | 43.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -33.33% |
| Total Other Non-Cash Items | -270.33% | 86.79% | -- | -- | -9.02% |
| Change in Net Operating Assets | -76.87% | 195.63% | -- | -- | 124.47% |
| Cash from Operations | 25.38% | 19.84% | -- | -- | 47.78% |
| Capital Expenditure | -- | 100.00% | -- | -- | 87.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -- | -- | 87.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 34.21% | -1.33% | -- | -- | -- |
| Issuance of Common Stock | -99.87% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.92% | 54,058.79% | -- | -- | -1,262.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -131.53% | 286.01% | -- | -- | 47.56% |